Altimmune (ALT) EBT Margin (2010 - 2025)
Altimmune (ALT) reported EBT Margin of 222653.85% for Q4 2025, up 68625385.0% year-over-year from N/an in Q4 2024, and up 158.55% quarter-over-quarter from 380280.0% in Q3 2025.
Altimmune (ALT) EBT Margin (2010 - 2025) Analysis & Trends
Altimmune (ALT) has 16 years of EBT Margin data on file, last reported at 222653.85% in Q4 2025.
- EBT Margin for Q4 2025 came in at 222653.85%, up 68625385.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 8600.0% (up 46669500.0% YoY), and the FY2025 annual result was 8600.0%, up 46669500.0% from the prior year.
- EBT Margin grew to 222653.85% in Q4 2025 per ALT's latest filing, from 380280.0% in the prior quarter.
- Over five years, EBT Margin peaked at 222653.85% in Q4 2025 and troughed at 1185650.0% in Q3 2022.
- A 5-year average of 232248.24% and a median of 173665.48% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 116444114 bps in 2022, then soared 117993978 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 164.24% in 2021, then jumped by 119745 bps to 196500.0% in 2022, then sank by 112 bps to 24029.73% in 2023, then sank by 1829 bps to 463600.0% in 2024, then surged by 148 bps to 222653.85% in 2025.
- Business Quant data shows ALT's EBT Margin at 222653.85% in Q4 2025, 380280.0% in Q3 2025, and 442920.0% in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 222,653.85% |
| Sep 30, 2025 | -380,280.00% |
| Jun 30, 2025 | -442,920.00% |
| Mar 31, 2025 | -405,120.00% |
| Dec 31, 2024 | -463,600.00% |
| Sep 30, 2024 | -456,900.00% |
| Jun 30, 2024 | -492,800.00% |
| Mar 31, 2024 | -487,880.00% |
| Dec 31, 2023 | -24,029.73% |
| Sep 30, 2023 | -5,710.22% |
| Jun 30, 2023 | -269,566.67% |
| Mar 31, 2023 | -95,680.95% |
| Dec 31, 2022 | 196,500.00% |
| Sep 30, 2022 | -1,185,650.00% |
| Jun 30, 2022 | -251,650.00% |
| Mar 31, 2022 | -61,062.50% |
| Dec 31, 2021 | -164.24% |
| Sep 30, 2021 | -21,208.86% |
| Jun 30, 2021 | -18,121.68% |
| Mar 31, 2021 | -1,773.76% |